Literature DB >> 6132674

Regional release of [3H]dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid.

M Marien, J Brien, K Jhamandas.   

Abstract

Previous studies have suggested that the release of dopamine (DA) in the rat brain may be sensitive to modulation by opioid agents, including the endogenous opioid peptides (enkephalins and endorphins). The present study examined the effects of morphine and the enkephalin analogue D-Ala2-Met5-enkephalinamide (DALA) on the release of radiolabeled DA from superfused slices of rat brain regions. The release of preloaded [3H]DA was evoked from slices of the caudate-putamen (CP) by application of potassium (K+), nicotine (NIC), or L-glutamic acid (L-GLU). The release of [3H]DA from slices of the nucleus accumbens (NA), olfactory tubercle (OT), and substantia nigra (SN) was evoked by L-GLU. Both K+ and NIC evoked a concentration-related release of [3H]DA from CP slices. K+-induced release was only partially dependent on calcium (Ca2+), while NIC-evoked release was completely Ca2+ independent. Neither morphine nor DALA influenced the release of [3H]DA evoked by K+ or NIC. L-GLU produced a concentration-dependent release of [3H]DA from slices of CP, NA, OT, and SN. In all four brain regions, this release was (a) Ca2+-dependent, (b) strongly inhibited by low concentrations of magnesium (Mg2+), (c) greater than the release evoked by D-GLU, (d) attenuated by the putative L-GLU receptor antagonist glutamic acid diethylester (GDEE), and (e) insensitive to tetrodotoxin (TTX) except in the SN. Morphine produced a significant inhibition of L-GLU-evoked [3H]DA release from all four regions. Naloxone, which by itself had no significant effect on the L-GLU-evoked release of [3H]DA, blocked the inhibitory effect of morphine on this release in the CP but not in the other regions. Levorphanol and dextrorphan were equipotent in reducing the glutamate-stimulated release of [3H]DA from CP slices. DALA had no effect on L-GLU-induced release in any of the brain regions examined. The results indicate that L-GLU provokes regional release of DA by acting at a Mg2+-sensitive glutamate receptor. This release is selectively modified by morphine through a mechanism which is insensitive to naloxone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132674     DOI: 10.1139/y83-005

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  10 in total

1.  Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration.

Authors:  T P Piepponen; J A Mikkola; M Ruotsalainen; D Jonker; L Ahtee
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; David Scheibal; Emily Hahn; Sharon Shiraga; Eleanor Zamora-Paja; Judah Farahi; Sanjaya Saxena; Edythe D London; James T McCracken
Journal:  Arch Gen Psychiatry       Date:  2006-07

Review 3.  Functional brain imaging of tobacco use and dependence.

Authors:  Arthur L Brody
Journal:  J Psychiatr Res       Date:  2005-06-24       Impact factor: 4.791

4.  Biochemical and pharmacological studies on a lethal neurotoxic polypeptide from Phoneutria nigriventer spider venom.

Authors:  L R Troncone; I Lebrun; F Magnoli; T Yamane
Journal:  Neurochem Res       Date:  1995-07       Impact factor: 3.996

Review 5.  In vivo brain imaging of human exposure to nicotine and tobacco.

Authors:  Anil Sharma; Arthur L Brody
Journal:  Handb Exp Pharmacol       Date:  2009

6.  In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids.

Authors:  K A Keefe; M J Zigmond; E D Abercrombie
Journal:  J Neural Transm Gen Sect       Date:  1993

7.  Glutamate-evoked release of endogenous brain dopamine: inhibition by an excitatory amino acid antagonist and an enkephalin analogue.

Authors:  K Jhamandas; M Marien
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

8.  Antagonism of the hypermotility response induced by excitatory amino acids in the rat nucleus accumbens.

Authors:  B A Donzanti; N J Uretsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

9.  Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

Review 10.  Presynaptic release-regulating NMDA receptors in isolated nerve terminals: A narrative review.

Authors:  Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2021-02-02       Impact factor: 9.473

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.